BioStock Studio: Cereno Scientific’s CEO about the milestone in the CS1 project

Report this content

Last week, Spotlight-listed Cereno Scientific got the acceptance from the FDA regarding their IND application for initiating a phase II trial with CS1 in the rare disease pulmonary arterial hypertension. CEO Sten R Sörensen visited BioStock’s studio and told us more about what this milestone means for Cereno Scientific.

Watch the interview in Swedish with Cereno Scientific’s CEO Sten R Sörensen at biostock.se:

https://www.biostock.se/en/2021/09/biostock-studio-cereno-scientifics-ceo-about-the-milestone-in-the-cs1-project/

This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se/

Subscribe

Quick facts

BioStock Studio: Cereno Scientific’s CEO about the milestone in the CS1 project
Tweet this